CSL making a funny move. Some snips "BioCryst will retain...

CSL making a funny move. Some snips

"BioCryst will retain responsibility for pandemic stockpiling of RAPIVAB in the US while bioCSL will have exclusive rights to pursue pandemic stockpiling outside the US."

"US company BioCryst Pharmaceuticals struck the RAPIVAB deal with CSL and will receive an upfront payment of $33.7m. BioCryst may receive up to $12m in additional payments related to the successful achievement of certain regulatory milestones."

"RAPIVAB, also known as peramivir, is not yet approved or available in Australia. CSL will have exclusive rights to commercialise RAPIVAB throughout the world except for Japan, South Korea, Taiwan and Israel."

http://www.theaustralian.com.au/bus...ights-to-rapivab/story-e6frg8zx-1227404747970